Preeclampsia, a gestational associated hypertension, has been reported in 6-8% of pregnant women worldwide leading to premature delivery and low birth weight of newborn due to reduced blood flow to placenta. Although several vasodilators (Methyl dopa, hydralazine, β-blockers and diuretics) are currently in use to treat preeclampsia, still there is a search for safer drugs with better efficacy. Lately, antihypertensive vasodilators from natural sources are gaining importance in treating preeclampsia. Eugenol (Eug), a natural essential oil, has been traditionally used in health and food products without any risk. In the present study, ex vivo experiments were designed to examine the vasorelaxation effect of Eug and its signaling pathways in a middle uterine artery (MUA) of pregnant Capra hircus ( Ch ). In presence of different blockers (L-NAME, indomethacin, ODQ, Ouabain, glibenclamide, 4-AP, Ba 2 , Carbenoxolone and 18β Glycyrrhetinic acid), Eug-induced concentration-dependent vasorelaxation response was elicited. The results showed that Eug caused a greater vasorelaxation effect in the MU of pregnant animals, which is mediated by potential activation of eNOS, K ATP channels, and K ir channels with moderate activation of Na + - K + - ATPase and sGC and MEGJ. These findings provide a strong basis for developing Eug as a therapeutic candidate in the treatment of pregnancy-associated hypertension.
Keyphrases
- pregnancy outcomes
- pregnant women
- blood pressure
- low birth weight
- blood flow
- preterm birth
- early onset
- preterm infants
- essential oil
- human milk
- healthcare
- public health
- hypertensive patients
- human health
- angiotensin converting enzyme
- signaling pathway
- pi k akt
- mental health
- drug induced
- diabetic rats
- gestational age
- risk assessment
- endothelial cells
- drinking water
- social media
- health information
- cell proliferation
- oxidative stress
- physical activity
- nitric oxide synthase
- health promotion
- endoplasmic reticulum stress